• 2011 Program

• 2011 Block Program

• 2011 Speakers

PROGRAM QUESTIONS?

Robert Lee Kilpatrick
Partner

Phone:
+1.831.464.4230

2:30-6:30  Early Registration & Check-In - Meritage Lobby

Visit the registration desk to check in on Tuesday which allows you to jump-start your networking opportunities at the Opening Reception!

By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Wednesday morning.

5:00-6:30  Opening Drinks Reception - Estate Wine Cave

Sponsored by: Deloitte & Touche LLP

Connect with fellow delegates on Tuesday evening before C21 BioVentures begins, over drinks and appetizers in the Estate Wine Cave at the Meritage Resort. The beautiful natural stone and dark woods combined with Old World Florentine architecture and furnishings will offer you an environment unlike any other.

8:30-4:30  Registration - Meritage Lobby

8:30-10:30  Continental Breakfast - Vineyard Terrace

Join us for a refreshing continental breakfast of fresh orange juice, muffins and breakfast pastries. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

8:45-9:15  Welcoming Remarks - Salons VII - X

Title: Sustaining California’s Biotechnology Leadership

Leaders of California’s biotechnology industry continue to move forward in the areas of innovation, business and global competitiveness. Key to this process is the coordination of bioclusters in Northern and Southern California. A roundtable discussion chaired by TVG, with the Presidents of BayBio, San Francisco and BioCom, San Diego will explore California’s “engine of innovation.”

Speaker: Dr. Robert Lee Kilpatrick, Partner, TVG
Speaker: Ms. Gail Maderis, President & CEO, BayBio
Speaker: Mr. Joe Panetta, President & CEO, BIOCOM

9:15-10:00  Keynote Address - Salons VII - X

Title: Financing Biotechnology in 2011 and Beyond

Speaker: Mr. Michael Gaito, Managing Director, J.P. Morgan

10:00-11:00  BioVenture Leadership Session - Salons VII - X

Title: BioVentures 2011: A Two Part Series on the State of Life Sciences Venture Investing

Session 1: State of the State

While venture dollars invested in life sciences companies increased slightly in 2010, rumors abound on the state of life sciences venture investing and whether the game is the same or whether we have a new game entirely. In this two part series, leading venture investors will discuss trends that lead up to the current state, clarifying facts about the current state and where we go from here.

Many factors have lead up to the current state of life sciences venture investing. This session will provide an overview of many of the statistics underlying the life sciences venture industry, as well as a discussion on the on some of the key trends and issues:


Chair: Mr. Eric Walczykowski, Recap and Life Sciences Accelerator, Deloitte & Touche LLP
Speaker: Mr. Chris Ehrlich, Managing Director, InterWest Partners
Speaker: Dr. Rodney A Ferguson, Managing Director, Panorama Capital
Speaker: Mr. Karl D Handelsman, Managing Director, CMEA Capital
Speaker: Mr. Jon Norris, Managing Director, SVB Capital

10:00-11:00  Coffee & Tea Service - Vineyard Pre-Function Area

Sponsored by: Aragen Bioscience, Inc.

10:00-5:00  Face-to-Face Meetings - powered by biopartnering.com™ - Salons I-III

All meetings scheduled through biopartnering.com will be held at the numbered tables in Salons I-III. Please visit the onsite Meeting & Message Desk for assistance.

11:00-12:30  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

11:00 Afraxis, Inc. - USA
11:15 Aquinox Pharmaceuticals Inc. - Canada
11:30 Nutrition 21, Inc. - USA
11:45 Applied Integrin Science, Inc. - USA
12:00 Mithridion Inc - USA
12:15 STATegics, Inc. - USA

11:00-12:30  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

11:00 Genentech, Inc. - USA
11:15 Savara - USA
11:45 Zymeworks - Canada
12:00 Del Mar Pharmaceuticals - Canada
12:15 Ascendis Pharma - Denmark

11:15-1:00  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
11:15-11:45	A B	Afraxis, Inc. Genentech, Inc.
11:30-12:00	C D	Aquinox Pharmaceuticals Inc. Savara
11:45-12:15	E	Nutrition 21, Inc.
12:00-12:30	A B	Applied Integrin Science, Inc. Zymeworks
12:15-12:45	C D	Mithridion Inc Del Mar Pharmaceuticals
12:30-1:00	E F	STATegics, Inc. Ascendis Pharma

12:30-1:30  Hot Buffet Lunch - Vineyard Terrace & Estate Wine Cave

1:30-2:30  Trends & Issues Session - Salons VII - X

Title: Partnering Trends: How The Economic Downturn Has Impacted Partnering Structures, Dynamics and Dealmaking Practices

A panel of experienced biotech and pharma dealmakers and investors comment on best partnering practices for 2011 and beyond, given the "new normal" the industry is experiencing. Topics will include defining a successful deal from all participants' viewpoints, anticipating and managing key challenges to executing partnering transactions in the current environment, and incorporating flexibility into the deal structure (using vehicles such as options to acquire the company, product rights or intellectual property rights), to allow the parties to manage their individual businesses and the collaboration in a changing environment.

Chair: Mrs. Judith A Hasko, Partner, Latham & Watkins
Chair: Mrs. Faye H Russell, Partner, Latham & Watkins
Speaker: Ms. Kathy Glaub, President, Plexxikon Inc.
Speaker: Mr. Paul Hastings, President & Chief Executive Officer, OncoMed Pharmaceuticals, Inc.
Speaker: Dr. Denise Pollard-Knight, Managing Partner, Phase4 Ventures

1:30-5:00  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

1:30 Susavion Biosciences, Inc - USA
1:45 Epic Sciences - USA
2:00 Finox Biotech - Switzerland
2:15 ADS Biotechnology - USA
2:30 Vidasym - USA
2:45 NAL Pharmaceuticals Ltd - Hong Kong
3:00 Juventas Therapeutics - USA
3:15 Fluxion Biosciences - USA
3:30 KAI Pharmaceuticals Inc. - USA
3:45 Fibralign Corporation - USA
4:00 Anaphore, Inc. - USA
4:15 VetDC, Inc. - USA
4:45 Receptos - USA

1:30-5:00  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

2:00 ACT Biotech - USA
2:15 SARcode Corporation - USA
2:30 ProNAi Therapeutics, Inc. - USA
2:45 ZaBeCor Pharmaceuticals - USA
3:00 Molecular Response - USA
3:15 ImmunGene - USA
3:30 Q Therapeutics, Inc. - USA
3:45 INAGEN - Denmark
4:00 Chimeros, Inc. - USA
4:15 Galera Therapeutics - USA
4:30 MannKind Corporation - USA
4:45 Hepregen Corporation - USA

1:45-5:45  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
1:45-2:15	A	Susavion Biosciences, Inc
2:00-2:30	C	Epic Sciences
2:15-2:45	E F	Finox Biotech ACT Biotech
2:30-3:00	A B	ADS Biotechnology SARcode Corporation
2:45-3:15	C D	Vidasym ProNAi Therapeutics, Inc
3:00-3:30	E F	NAL Pharmaceuticals Ltd ZaBeCor Pharmaceuticals
3:15-3:45	A B	Juventas Therapeutics Molecular Response
3:30-4:00	C D	Fluxion Biosciences ImmunGene
3:45-4:15	E F	KAI Pharmaceuticals Inc. Q Therapeutics, Inc.
4:00-4:30	A B	Fibralign Corporation INAGEN
4:15-4:45	C D	Anaphore, Inc.  Chimeros, Inc.
4:30-5:00	E F	VetDC, Inc. Galera Therapeutics
4:45-5:15	B	Mannkind Corporation
5:00-5:30	C D	Receptos Hepregen Corporation

2:30-5:00  Coffee & Tea Service - Vineyard Pre-Function Area

Sponsored by: Aragen Bioscience, Inc.

6:00-6:30  Bus Transportation to Reception - Front of Meritage Lobby

Coaches will transport delegates to the Franciscan Winery for the networking reception.

Coaches will shuttle between the reception and the Meritage Resort until 8:30 PM, when the final bus will leave the reception for a return trip to the Meritage Resort.

No transportation or drop-offs will be provided to other locations.

6:30-8:30  Networking Reception - Franciscan Winery

Join us for a relaxing evening of classic California wine, delicious hors d'oeuvres, and casual networking. The reception will be indoors with an optional outdoor patio. Please dress warmly if the weather is cool.

8:30-4:30  Registration - Meritage Lobby

8:30-10:30  Continental Breakfast - Vineyard Terrace

Join us for a continental breakfast of fresh fruit juices, breakfast pastries accompanied by sweet cream butter and fruit preserves, sliced seasonal fruits and berries, and an assortment of yogurts. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

9:00-9:45  Keynote Address - Salons VII - X

Title: Reshaping Biogen Idec: Chapters 1 and 2

Speaker: Dr. George A Scangos, Chief Executive Officer, Biogen Idec Inc.

9:30-3:30  Face-to-Face Meetings - powered by biopartnering.com™ - Salons I-III

All meetings scheduled through biopartnering.com will be held at the numbered tables in Salons I-III. Please visit the onsite Meeting & Message Desk for assistance.

9:45-10:45  BioVenture Leadership Session - Salons VII - X

Title: BioVentures 2011: A Two-Part Series on the State of Life Sciences Venture Investing
Session 2: The Future of the State--What's Happening To The Life Sciences Venture Capital Industry And What Does It Mean To You?

In this panel, the second part of a two-part series on the state of the venture capital industry, we'll explore what the future looks like for venture funds, for the life sciences industry and for global health, based on the conclusions reached in the Part 1 panel the previous day. If the rumors of a "forest-fire" in the venture capital industry, not just in the US but also globally, are true, what does this mean for a start-up seeking funding as well as for more mature pre-public companies who need large follow-on financing? If venture money is going to be scarce, what will take its place--or will the number of funded companies shrink dramatically as a result of a shrinking pool of life sciences venture funding? And what does it mean for the funds themselves? Will the way in which venture funds are structured, and in which their partners operate and are rewarded, change?

A panel of seasoned venture capital fund partners will dive deeply and candidly into the hot topic of how what's really going on in the life sciences venture capital industry will affect our industry and what it means to companies now and in the future, discussing, among other key topics, the future of pre-public financing for the life sciences industry, the future design and model of successful life sciences companies and the implications for the pace of progress of scientific discovery and commercialization, and leadership in innovation and technology, that may result from this capital drought.


Chair: Mr. Bruce W Jenett, Co-Chair, Global Life Sciences Sector, DLA Piper LLP (US)
Speaker: Dr. Jens E Eckstein, Venture Partner and Entrepreneur-in-Residence, TVM Capital
Speaker: Mr. Ken Haas, Venture Partner, Abingworth Management, Ltd.
Speaker: Mr. Jack B Nielsen, Partner, Novo A/S
Speaker: Dr. Nandini Tandon, Managing Director, Lumira Capital Corp

9:45-10:45  Coffee & Tea Service - Vineyard Pre-Function Area

Sponsored by: Aragen Bioscience, Inc.

10:45-12:30  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

10:45 KromaTiD - USA
11:15 NeuroQuest Inc. - Canada
11:30 Fluxome A/S - Denmark
11:45 Apeiron Biologics Gmbh - Austria
12:00 Embera NeuroTherapeutics - USA
12:15 13therapeutics - USA

10:45-12:30  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

10:45 Molecular Templates Inc. - USA
11:00 Virobay, Inc. - USA
11:15 Galenea Corp. - USA
11:30 Biovista, Inc. - USA
11:45 Ruga Corporation - USA
12:00 NEUROTEZ, INC. - USA
12:15 Mayfield Bioscience, Inc. - USA

11:00-1:15  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
11:00-11:30	A B	KromaTiD Molecular Templates Inc.
11:15-11:45	D	Virobay, Inc.
11:30-12:00	E F	NeuroQuest Inc. Galenea Corp.
11:45-12:15	A B	Fluxome A/S Biovista, Inc.
12:00-12:30	C D	Apeiron Biologics Gmbh Ruga Corporation
12:15-12:45	E F	Embera NeuroTherapeutics NEUROTEZ, INC.
12:30-1:00	A B	13therapeutics Mayfield Bioscience, Inc.

12:30-1:30  Hot Buffet Lunch - Vineyard Terrace & Estate Wine Cave

1:30-2:30  Trends & Issues Session - Salons VII - X

Title: Creative Financing in Challenging Times: Looking at all available options

Today's difficult financial market for public companies requires management to explore a variety of financing options including equity, structured debt and revenue monetization. A panel of industry experts will explore the various options available including PIPEs, Registered Directs, and "Wall-crossed" (Pre-marketed) financings as well as CEFFs and Royalty and Revenue Interest (Synthetic royalty) transactions and discuss the advantages and disadvantages of these alternatives under different circumstances. Now more than ever it is vital for management to understand the full range of equity and non-dilutive financing options available to them.

Chair: Mr. Michael J O'Donnell, Partner, Morrison & Foerster
Speaker: Mr. Ben Colombo, Senior Relationship Manager, SVB Silicon Valley Bank
Speaker: Mr. Paul Hadden, Vice President, Cowen Healthcare Royalty Partners
Speaker: Mr. Brad Wolff, Director, Leerink Swann

1:30-3:30  Podium Presentations - Stream 1 - Salon VI

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

1:30 My Mercury Risk, Inc. - USA
1:45 MetaSignal Therapeutics Inc - Canada
2:00 Presbia Cooperatief - USA
2:15 Pacific Biosciences - USA
2:30 EyeCyte Inc. - USA
2:45 Omniox, Inc. - USA
3:15 Formatech Inc. - USA

1:30-3:30  Podium Presentations - Stream 2 - Salon IV

In this dedicated presentation room, biotechnology companies from around the world will introduce their companies, their key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.

1:30 CENTROSE - USA
1:45 Trellis Bioscience, Inc. - USA
2:00 SEA Medical Systems - USA
2:15 DermTech International - USA
2:30 Phoenix PharmaLabs, Inc. - USA
2:45 Delpor, Inc. - USA
3:00 Aethlon Medical, Inc. - USA
3:15 NextWave Pharmaceuticals - USA

1:45-4:15  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Table Time	Table Assignment	Company Name
1:45-2:15	C D	My Mercury Risk, Inc. CENTROSE
2:00-2:30	E F	MetaSignal Therapeutics Inc.  Trellis Bioscience, Inc.
2:15-2:45	A B	Presbia Cooperatief SEA Medical Systems
2:30-3:00	C D	Pacific Biosciences DermTech International
2:45-3:15	E F	EyeCyte Inc. Phoenix PharmaLabs, Inc.
3:00-3:30	A B	Omniox, Inc. Delpor, Inc.
3:15-3:45	D	Aethlon Medical, Inc.
3:30-4:00	E F	Formatech, Inc. NextWave Pharmaceuticals

2:30-3:30  Coffee & Tea Service - Vineyard Pre-Function Area

Sponsored by: Aragen Bioscience, Inc.

3:30-5:00  Closing Drinks Reception - Vineyard Terrace

An opportunity to say goodbye to fellow delegates and begin planning for C21 BioVentures 2012.